001065343 Stock Overview Provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Edwards Lifesciences Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for Edwards Lifesciences Historical stock prices Current Share Price US$65.79 52 Week High US$0 52 Week Low US$0 Beta 1.13 1 Month Change 12.94% 3 Month Change n/a 1 Year Change n/a 3 Year Change -55.02% 5 Year Change 8.56% Change since IPO 153.04%
Recent News & Updates
Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data Nov 26
Third quarter 2024 earnings released: EPS: US$0.61 (vs US$0.55 in 3Q 2023) Nov 08
Edwards Lifesciences Corporation Presents Data at TCT Reinforce Commitment to Structural Heart Innovation Nov 02
TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation Oct 30
Edwards Lifesciences Announces Results from the EARLY TAVR Trial Oct 29
Edwards Lifesciences Corporation Provides Earnings Guidance for the Fourth Quarter and Reiterates Sales Guidance for the Full Year 2024 Oct 25 See more updates
Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data Nov 26
Third quarter 2024 earnings released: EPS: US$0.61 (vs US$0.55 in 3Q 2023) Nov 08
Edwards Lifesciences Corporation Presents Data at TCT Reinforce Commitment to Structural Heart Innovation Nov 02
TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation Oct 30
Edwards Lifesciences Announces Results from the EARLY TAVR Trial Oct 29
Edwards Lifesciences Corporation Provides Earnings Guidance for the Fourth Quarter and Reiterates Sales Guidance for the Full Year 2024 Oct 25
Edwards Lifesciences Corporation to Report Q3, 2024 Results on Oct 24, 2024 Oct 17
Robbins Geller Rudman & Dowd LLP Updates on Class Action Lawsuit Against Edwards Lifesciences Corporation Oct 15
Edwards Launches SAPIEN 3 With Alterra Prestent in Europe for Transcatheter Pulmonic Valve Implantation Sep 17 Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW). Sep 04
Edwards Lifesciences Corporation Provides Earnings Guidance for the Third Quarter of 2024
Edwards Lifesciences Corporation (NYSE:EW) agreed to acquire the remaining unknown majority stake in Innovalve Bio Medical Ltd. for $300 million. Jul 15
Edwards Lifesciences Announces Results from Analysis of Data from Partner Trials Examining Outcomes of Transcatheter Aortic Valve Replacement Patients with Small Annulus Jun 06
Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion. Jun 05
Edwards Lifesciences Corporation Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability May 09 Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024
Edwards Lifesciences Corporation to Report Q1, 2024 Results on Apr 25, 2024 Apr 20
Edwards Lifesciences Announces the Release of Data from the Hudle Study Apr 09
Insufficient new directors Apr 06
Edwards Lifesciences Corporation, Annual General Meeting, May 07, 2024 Mar 27
Edwards Lifesciences Announces Large, Real-World Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR Mar 12
Investor sentiment improves as stock rises 25% Mar 06
Insufficient new directors Mar 06
Edwards Lifesciences Corporation Provides Earnings Guidance for the First Quarter and Full Year 2024 Feb 07
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve Feb 02 Edwards Lifesciences Corporation to Report Q4, 2023 Results on Feb 06, 2024 Jan 31
Insufficient new directors Jan 08
Edwards Lifesciences Corporation Reaffirms Earnings Guidance for the Year 2023 and Provides Earnings Guidance for the Full Year 2024 Dec 08
Edwards Lifesciences Corporation (NYSE:EW) announces an Equity Buyback for $1,000 million worth of its shares. Dec 07
Clasp IID One-Year Data Confirm Safety and Efficacy of Edwards Pascal System for Degenerative Mitral Regurgitation Oct 29 Edwards Lifesciences Corporation Provides Earnings Guidance for Full Year 2023 and Fourth Quarter of 2023
Edwards Lifesciences Corporation's Evoque Tricuspid Valve Replacement System Receives CE Mark Oct 20
Edwards Lifesciences Corporation to Report Q3, 2023 Results on Oct 25, 2023 Oct 19
Edwards Lifesciences Corporation Announces the Results of the Eu-Hyprotect Registry Aug 15
Insufficient new directors Aug 11 Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023 Jul 28
Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023 Jul 27
Edwards Lifesciences Announces Results of the EU-HYPROTECT Registry Jun 09
Edwards' Aortic Valve with Resilia Tissue Shows Favorable Durability, Safety and Efficacy Outcomes in Seven Year Data May 18
First quarter 2023 earnings released: EPS: US$0.56 (vs US$0.60 in 1Q 2022) Apr 28
Edwards Lifesciences Corporation to Report Q4, 2022 Results on Jan 31, 2023 Jan 25
Edwards Lifesciences Corporation Provides Earnings Guidance for the Full Year 2023 Jan 12 Edwards Lifesciences Corporation, Annual General Meeting, May 11, 2023
Edwards Lifesciences Corporation Announces One-Year Data on Transfemoral Transcatheter Tricuspid Valve Replacement Nov 28
Edwards Lifesciences Corporation to Report Q3, 2022 Results on Oct 27, 2022 Oct 21
Edwards Lifesciences Corporation Announces Results from CLASP IID Sep 20
Edwards Lifesciences Corporation's Transcatheter Edge-To-Edge Repair Receives FDA Approval Sep 16
Edwards Lifesciences Corporation Launches SAPIEN 3 Ultra Resilia Valve Following FDA Approval Sep 13 Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year of 2022
Edwards Lifesciences Corporation to Report Q2, 2022 Results on Jul 28, 2022 Jul 22
Investor sentiment deteriorated over the past week Jun 20
Edwards Lifesciences Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2022 Apr 27
Edwards Lifesciences Corporation to Report Q1, 2022 Results on Apr 26, 2022 Apr 20
Edwards Lifesciences Corporation's MITRIS RESILIA Valve Receives FDA Approval for Mitral Replacement Surgeries Apr 01
Investor sentiment deteriorated over the past week Mar 29
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Jan 27
Edwards Lifesciences Provides Earnings Guidance for the First Quarter and Full Year of 2022 Jan 27
Edwards Lifesciences Corporation Receives FDA Approval for SAPIEN 3 with Alterra Prestent for Transcatheter Pulmonic Valve Replacement Dec 21
Edwards Lifesciences Corporation Provides Sales Guidance for Fiscal 2022 Dec 09
Independent Director recently bought CHF158k worth of stock Nov 30
Third quarter 2021 earnings released: EPS US$0.55 (vs US$0.52 in 3Q 2020) Oct 28
Second quarter 2021 earnings released: EPS US$0.79 (vs US$0.20 loss in 2Q 2020) Jul 31
Edwards Lifesciences Announces Clinical and Economic Results from 3M Transcatheter Aortic Valve Replacement Economic Study and the Partner 3 Bicuspid Registry for SAPIEN 3 TAVR Study Jul 25
Edwards Lifesciences Receives U.S. Food and Drug Administration Clearance for Hypotension Prediction Index Software for Noninvasive Acumen IQ Cuff Jun 02 Edwards Lifesciences Corporation Presents Clinical Results from Transcatheter Mitral and Tricuspid Programs as Part of the Late-Breaking Clinical Trials at EuroPCR 2021
Independent Director has left the company May 10
Edwards Lifesciences Corporation (NYSE:EW) announces an Equity Buyback for $1,000 million worth of its shares. May 06
VP & Corporate Controller recently sold CHF1.1m worth of stock Apr 25
First quarter 2021 earnings released: EPS US$0.54 (vs US$0.50 in 1Q 2020) Apr 24
Edwards Lifesciences Corporation Provides Earnings Guidance for the Full Year 2021 Apr 23
Revenue beats expectations Feb 14
Full year 2020 earnings released: EPS US$1.32 (vs US$1.68 in FY 2019) Feb 14
Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years Feb 01
Full year 2020 earnings released: EPS US$1.32 (vs US$1.68 in FY 2019) Jan 29
Revenue beats expectations Jan 29
Edwards Lifesciences Corporation to Report Q4, 2020 Results on Jan 27, 2021 Jan 14
Edwards SAPIEN 3 TAVI Receives Expanded Approval in Canada Dec 20
Third quarter earnings released Oct 22
Third-quarter earnings released: Revenue beats expectations Oct 22
Edwards Lifesciences Corporation to Report Q3, 2020 Results on Oct 21, 2020 Oct 08 Sangamo BioSciences, Inc. has entered into a definitive asset purchase agreement to acquire angiogenesis program from and Edwards Lifesciences Corporation for $7.5 million.
Insider recently sold CHF548.3k worth of stock Sep 03 Shareholder Returns 001065343 CH Medical Equipment CH Market 7D 5.7% -1.2% -2.3% 1Y n/a 1.7% 0.7%
See full shareholder returns
Return vs Market: Insufficient data to determine how 001065343 performed against the Swiss Market .
Price Volatility Is 001065343's price volatile compared to industry and market? 001065343 volatility 001065343 Average Weekly Movement n/a Medical Equipment Industry Average Movement 3.8% Market Average Movement 3.2% 10% most volatile stocks in CH Market 7.4% 10% least volatile stocks in CH Market 1.6%
Stable Share Price: 001065343's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine 001065343's volatility change over the past year.
About the Company Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve.
Show more Edwards Lifesciences Corporation Fundamentals Summary How do Edwards Lifesciences's earnings and revenue compare to its market cap? 001065343 fundamental statistics Market cap CHF 39.40b Earnings (TTM ) CHF 1.40b Revenue (TTM ) CHF 5.64b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 001065343 income statement (TTM ) Revenue US$6.31b Cost of Revenue US$1.48b Gross Profit US$4.84b Other Expenses US$3.27b Earnings US$1.57b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 2.66 Gross Margin 76.60% Net Profit Margin 24.82% Debt/Equity Ratio 6.2%
How did 001065343 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 15:41 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Edwards Lifesciences Corporation is covered by 74 analysts. 33 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Francis Mainwaring Atlantic Equities LLP David Rescott Baird Ishan Majumdar Baptista Research
Show 71 more analysts 
